Senate Files

Bills

S. 4583 118th Congress

Creating Hope Reauthorization Act of 2024

Latest action, Jun 18, 2024: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

9 cosponsors

Sponsored by Robert P. Casey, Jr. (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
5 D · 4 R
  • Democrat
  • Republican
  • Independent
9 senators cosponsoring

Referred to: Senate: Health, Education, Labor, and Pensions Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

25 clientsQ2 2024Q4 2024

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

ACADIA PHARMACEUTICALS
3 reports
BAYER CORPORATION (CONSOLIDATED REPORT)
3 reports
BIOMARIN PHARMACEUTICAL INC.
3 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
AKIN GUMP STRAUSS HAUER & FELD
3 reports
CHIESI USA, INC.
SPLITOAK STRATEGIES LLC
3 reports
CURE SMA
3 reports
GENETIX BIOTHERAPEUTICS, INC.
ARNOLD & PORTER KAYE SCHOLER LLP
3 reports
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)
3 reports
TRAVERE THERAPEUTICS
3 reports
ACADIA PHARMACEUTICALS, INC.
TIBER CREEK GROUP
2 reports
ALLIANCE FOR REGENERATIVE MEDICINE
2 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
2 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
2 reports
BRIDGEBIO PHARMA, INC.
2 reports
IONIS PHARMACEUTICALS, INC.
2 reports
The top 25 of 27 clients, by reports
ClientLobbying firmReportsReports totalingFromToSenate
ACADIA PHARMACEUTICALS3$1.2MQ4 2024Q3 2024yes
BAYER CORPORATION (CONSOLIDATED REPORT)3$6.2MQ4 2024Q3 2024yes
BIOMARIN PHARMACEUTICAL INC.3$910KQ4 2024Q3 2024yes
BIOTECHNOLOGY INNOVATION ORGANIZATIONAKIN GUMP STRAUSS HAUER & FELD3$0Q4 2024Q3 2024yes
CHIESI USA, INC.SPLITOAK STRATEGIES LLC3$0Q4 2024Q3 2024yes
CURE SMA3$225KQ4 2024Q3 2024yes
GENETIX BIOTHERAPEUTICS, INC.ARNOLD & PORTER KAYE SCHOLER LLP3$180KQ4 2024Q3 2024yes
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)3$100KQ4 2024Q3 2024yes
TRAVERE THERAPEUTICS3$360KQ4 2024Q3 2024yes
ACADIA PHARMACEUTICALS, INC.TIBER CREEK GROUP2$0Q4 2024Q3 2024yes
ALLIANCE FOR REGENERATIVE MEDICINE2$350KQ4 2024Q3 2024yes
BIOTECHNOLOGY INNOVATION ORGANIZATION2$3.1MQ4 2024Q3 2024yes
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)2$160KQ4 2024Q3 2024yes
BRIDGEBIO PHARMA, INC.2$500KQ4 2024Q3 2024yes
IONIS PHARMACEUTICALS, INC.2$160KQ4 2024Q3 2024yes
MIGHTY THERAPEUTICS (FMRLY STEALTH BIOTHERAPEUTICS INC.)2$80KQ4 2024Q3 2024yes
PATIENTS RISING NOWYC CONSULTING, LLC2$160KQ4 2024Q3 2024yes
PRAXIS PRECISION MEDICINESTHE KPM GROUP DC LLC2$60KQ4 2024Q3 2024yes
SHIONOGI INC.2$170KQ4 2024Q3 2024yes
ULTRAGENYX PHARMACEUTICAL, INC.MEHLMAN CONSULTING, INC.2$0Q4 2024Q3 2024yes
YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOWLONG STRATEGIES, INC.2$20KQ4 2024Q3 2024yes
ASTRIA THERAPEUTICS, INC.THE KPM GROUP DC LLC1$40KQ3 2024Q3 2024yes
EPILEPSY FOUNDATION1$60KQ4 2024Q4 2024yes
FULCRUM THERAPEUTICS, INC.THE KPM GROUP DC LLC1$60KQ3 2024Q3 2024yes
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)FAEGRE DRINKER BIDDLE & REATH LLP1$0Q4 2024Q4 2024yes